Global Pharmaceutical Business Focused on Fibrosis Therapies
First written in FY2016-Q2. 12 of 26 entries say "Restated". Latest entry: 2026-08-18.
No other company in this theme has enough history to compare yet.
- 2026-08-18OtherEarnings presentation
「30」
The description of the principal Group structure states that there are 30 subsidiaries and affiliates. However, this document does not provide a breakdown of consolidated subsidiaries and affiliates or explain the basis for calculating the number of companies compared with previous figures. - FY2026-H1Increase to 25 consolidated subsidiariesAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 25 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we conduct research and development and the manufacture and sale of development compounds centered on Etuary, sold in the Chinese market, and F351, for which clinical trials have been completed. In the medical devices business, based in the United States, we develop and manufacture and sell medical devices, including biomaterials.」
The number of consolidated subsidiaries increased from 24 to 25, with 2 associates also included. The two business segments, pharmaceuticals and medical devices, remain unchanged. - FY2025Update to the consolidated group structureAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 24 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The number of companies remained 24 consolidated subsidiaries and 2 associates, but the group structure changed after the investment relationship with Governance Partners ASIA Investment Limited Partnership was terminated in December 2025 and ZOO LABO was made a consolidated subsidiary. - FY2024Increase to 24 consolidated subsidiariesAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 24 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The group expanded from 18 consolidated subsidiaries and 2 associates to 24 consolidated subsidiaries and 2 associates. Its business activities remain divided into pharmaceuticals and medical devices. - FY2024-H1Increase in consolidated subsidiaries and consolidation of an investment partnershipAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 18 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we conduct research and development, manufacturing and sales of Etuary, sold in the Chinese market, and development compounds centered on F351, which is undergoing clinical trials. In the medical devices business, based in the United States, we develop, manufacture and sell medical devices, including biomaterials.」
The group structure was updated from 17 consolidated subsidiaries and 2 associates to 18 consolidated subsidiaries and 2 associates. Governance Partners ASIA Investment Limited Partnership was included in the scope of consolidation from the second-quarter consolidated accounting period. - FY2024-Q1Update to the consolidated group structureAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 17 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The group structure was updated from 14 consolidated subsidiaries and 2 associates to 17 consolidated subsidiaries and 2 associates. The two business segments, pharmaceuticals and medical devices, remain unchanged. - FY2023-Q1Update to the consolidated group structureAnnual report
「Our group consists of the company, which prepares consolidated financial statements, 14 consolidated subsidiaries and 2 equity-method associates. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The business remains divided into pharmaceuticals and medical devices, while the group structure disclosed comprises 14 consolidated subsidiaries and 2 associates. - FY2022-Q3RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In the medical devices business, based primarily in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group continues to operate through two business segments, pharmaceuticals and medical devices, with 15 consolidated subsidiaries. - FY2022-Q1RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business. In the pharmaceuticals business, we manufacture and sell Etuary in the Chinese market and conduct clinical trials focused on additional indications for Etuary and F351. In the medical devices business, based primarily in the United States, we manufacture and sell medical devices, including biomaterials, developed independently by our group.」
The group continues to consist of 15 consolidated subsidiaries and to operate globally through its pharmaceuticals and medical devices businesses. - FY2021ReframedAnnual report
「As a multinational healthcare company, our group’s mission is to bring hope to patients worldwide through the development, market development and commercialization, manufacturing and sale of technologies and products that address unmet medical needs, meaning medical needs for diseases for which no effective treatment exists.」
The company broadened its positioning from a global pharmaceutical company to a multinational healthcare company whose mission is to address unmet medical needs. - FY2021-Q3RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The group consists of 15 consolidated subsidiaries and continues to position itself as a global life sciences company operating in the pharmaceuticals and medical devices businesses. - FY2021-Q2RestatedAnnual report
「Our group consists of the company, which prepares consolidated financial statements, and 15 consolidated subsidiaries. Its business activities are classified into the pharmaceuticals business and the medical devices business.」
The company continues to position itself as a global life sciences company whose principal business areas are pharmaceuticals and medical devices. - FY2019RestatedAnnual report
「As a multinational biopharmaceutical company, our group’s primary objective is to discover, develop and commercialize treatments for diseases associated with unmet medical needs.」
The company continues to position itself as a global company centered on pharmaceuticals, medical devices and drug discovery as a multinational biopharmaceutical company. - FY2019-Q3ReframedAnnual report
「Our group is a global pharmaceutical company headquartered in Tokyo, Japan, engaged in the pharmaceuticals, biomaterials and medical devices, and drug discovery businesses.」
Drug discovery was explicitly added to the company’s positioning alongside its existing pharmaceuticals and biomaterials and medical devices businesses, broadening the description of its business areas. - FY2019-Q2RestatedAnnual report
「Headquartered in Japan, we are a global pharmaceutical company engaged in the pharmaceuticals and medical devices businesses through subsidiaries in China and the United States.」
The company continues to position itself as a global pharmaceutical company headquartered in Japan and conducting pharmaceutical and medical device operations through subsidiaries in China and the United States. - FY2018-Q3RestatedAnnual report
「Headquartered in Japan, we are a global pharmaceutical company operating primarily through subsidiaries in China and the United States. Our business areas are pharmaceuticals and medical devices.」
The company continues to position itself as a global company headquartered in Japan and operating primarily through subsidiaries in China and the United States in the pharmaceuticals and medical devices businesses. - FY2018-Q2RestatedAnnual report
「Headquartered in Japan, we have subsidiaries in China and the United States and are a global pharmaceutical company whose principal business areas are pharmaceuticals and medical devices.」
The company reiterates its positioning as a global pharmaceutical company headquartered in Japan and operating in pharmaceuticals and medical devices in China and the United States. - FY2018-Q1RestatedAnnual report
「Headquartered in Japan, we have subsidiaries in China and the United States and are a global pharmaceutical company whose principal business areas are pharmaceuticals and medical devices.」
The company reiterates its positioning as a global company operating in pharmaceuticals and medical devices, with operations in China and the United States. - FY2017RestatedAnnual report
「Our group is a global life sciences company operating in China, Japan and the United States.」
The company continues to position itself as a global life sciences company encompassing pharmaceuticals and medical devices. - FY2017-Q3ReframedAnnual report
「Our group is a global life sciences company focused on pharmaceutical products and medical devices, including biomaterials.」
The company’s positioning broadened from a global pharmaceutical company focused on fibrosis therapies to a global life sciences company focused on pharmaceuticals and medical devices, including biomaterials. - FY2017-Q2RestatedAnnual report
「Our group is a global pharmaceutical company engaged in the research and development, manufacturing and sale of fibrosis-related therapies in Asia and worldwide, with a primary focus on Japan, China and the United States.」
The company reiterates its positioning as a global pharmaceutical company conducting research and development, manufacturing and sales of fibrosis-related therapies, primarily in Japan, China and the United States. - FY2017-Q1RestatedAnnual report
「Our group is a global pharmaceutical company engaged in the research and development, manufacturing and sale of fibrosis-related therapies in Asia and worldwide, with a primary focus on Japan, China and the United States.」
The company reiterates its positioning as a global pharmaceutical company conducting research and development, manufacturing and sales of fibrosis-related therapies, primarily in Japan, China and the United States. - FY2016-Q2First statedAnnual report
「Our group is a global pharmaceutical company engaged in the research and development, manufacturing and sale of fibrosis-related therapies in Asia and worldwide, with a primary focus on Japan, China and the United States.」
The company describes itself as a global pharmaceutical company conducting research and development, manufacturing and sales of fibrosis-related therapies, primarily in Japan, China and the United States.